TY - JOUR
T1 - Obstetrical APS: Is there a place for hydroxychloroquine to improve the pregnancy outcome?
AU - Mekinian, Arsene
AU - Costedoat-Chalumeau, Nathalie
AU - Masseau, Agathe
AU - Tincani, Angela
AU - De Caroli, Sara
AU - Alijotas-Reig, Jaume
AU - Ruffatti, Amelia
AU - Ambrozic, Ales
AU - Botta, Angela
AU - Le Guern, Véronique
AU - Fritsch-Stork, Ruth
AU - Nicaise-Roland, Pascale
AU - Carbonne, Bruno
AU - Carbillon, Lionel
AU - Fain, Olivier
PY - 2015/1/1
Y1 - 2015/1/1
N2 - © 2014 Elsevier B.V.. The use of the conventional APS treatment (the combination of low-dose aspirin and LMWH) dramatically improved the obstetrical prognosis in primary obstetrical APS (OAPS). The persistence of adverse pregnancy outcome raises the need to find other drugs to improve obstetrical outcome. Hydroxychloroquine is widely used in patients with various autoimmune diseases, particularly SLE. Antimalarials have many anti-inflammatory, anti-aggregant and immune-regulatory properties: they inhibit phospholipase activity, stabilize lysosomal membranes, block the production of several pro-inflammatory cytokines and, in addition, impair complement-dependent antigen-antibody reactions. There is ample evidence of protective effects of hydroxychloroquine in OAPS similar to the situation in SLE arising from in vitro studies of pathophysiological working mechanism of hydroxychloroquine. However, the clinical data on the use of hydroxychloroquine in primary APS are lacking and prospective studies are necessary.
AB - © 2014 Elsevier B.V.. The use of the conventional APS treatment (the combination of low-dose aspirin and LMWH) dramatically improved the obstetrical prognosis in primary obstetrical APS (OAPS). The persistence of adverse pregnancy outcome raises the need to find other drugs to improve obstetrical outcome. Hydroxychloroquine is widely used in patients with various autoimmune diseases, particularly SLE. Antimalarials have many anti-inflammatory, anti-aggregant and immune-regulatory properties: they inhibit phospholipase activity, stabilize lysosomal membranes, block the production of several pro-inflammatory cytokines and, in addition, impair complement-dependent antigen-antibody reactions. There is ample evidence of protective effects of hydroxychloroquine in OAPS similar to the situation in SLE arising from in vitro studies of pathophysiological working mechanism of hydroxychloroquine. However, the clinical data on the use of hydroxychloroquine in primary APS are lacking and prospective studies are necessary.
KW - Antiphospholipid syndrome
KW - Hydroxychloroquine
KW - Outcome
U2 - 10.1016/j.autrev.2014.08.040
DO - 10.1016/j.autrev.2014.08.040
M3 - Review article
SN - 1568-9972
VL - 14
SP - 23
EP - 29
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 1
ER -